KR102770849B1 - 향상된 il-6 항체 - Google Patents

Info

Publication number

KR102770849B1

KR102770849B1 KR1020247004699A KR20247004699A KR102770849B1 KR 102770849 B1 KR102770849 B1 KR 102770849B1 KR 1020247004699 A KR1020247004699 A KR 1020247004699A KR 20247004699 A KR20247004699 A KR 20247004699A KR 102770849 B1 KR102770849 B1 KR 102770849B1

Authority

KR

South Korea

Prior art keywords

antibody

antigen

seq

binding fragment

delete delete

Prior art date

2014-11-07

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 400
• 206010012688 Diabetic retinal oedema Diseases 0.000 claims abstract description 44
• 201000011190 diabetic macular edema Diseases 0.000 claims abstract description 44
• 230000027455 binding Effects 0.000 claims description 342
• 239000012634 fragment Substances 0.000 claims description 282
• 239000000427 antigen Substances 0.000 claims description 228
• 108091007433 antigens Proteins 0.000 claims description 226
• 102000036639 antigens Human genes 0.000 claims description 226
• 239000000203 mixture Substances 0.000 claims description 99
• 150000001413 amino acids Chemical class 0.000 claims description 57
• 229960003989 tocilizumab Drugs 0.000 claims description 40
• 238000011282 treatment Methods 0.000 claims description 28
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 26
• 150000007523 nucleic acids Chemical class 0.000 claims description 25
• 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 22
• 108010029485 Protein Isoforms Proteins 0.000 claims description 19
• 102000001708 Protein Isoforms Human genes 0.000 claims description 19
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 18
• 208000002780 macular degeneration Diseases 0.000 claims description 18
• 238000003556 assay Methods 0.000 claims description 17
• 208000008795 neuromyelitis optica Diseases 0.000 claims description 16
• 208000004644 retinal vein occlusion Diseases 0.000 claims description 16
• 206010013774 Dry eye Diseases 0.000 claims description 15
• 102000039446 nucleic acids Human genes 0.000 claims description 15
• 108020004707 nucleic acids Proteins 0.000 claims description 15
• 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 15
• 206010038848 Retinal detachment Diseases 0.000 claims description 14
• 208000019793 rhegmatogenous retinal detachment Diseases 0.000 claims description 14
• 206010046851 Uveitis Diseases 0.000 claims description 12
• 108010081667 aflibercept Proteins 0.000 claims description 11
• 230000014759 maintenance of location Effects 0.000 claims description 8
• 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 5
• 229960002833 aflibercept Drugs 0.000 claims description 5
• 208000002205 allergic conjunctivitis Diseases 0.000 claims description 5
• 208000024998 atopic conjunctivitis Diseases 0.000 claims description 5
• 239000008194 pharmaceutical composition Substances 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 70
• 201000010099 disease Diseases 0.000 abstract description 56
• 208000022873 Ocular disease Diseases 0.000 abstract description 18
• 102000004889 Interleukin-6 Human genes 0.000 description 394
• 210000004027 cell Anatomy 0.000 description 84
• 238000000034 method Methods 0.000 description 71
• 210000001508 eye Anatomy 0.000 description 69
• 230000035772 mutation Effects 0.000 description 64
• 108090000765 processed proteins & peptides Proteins 0.000 description 61
• 241000282414 Homo sapiens Species 0.000 description 57
• 235000001014 amino acid Nutrition 0.000 description 57
• 230000036515 potency Effects 0.000 description 51
• 108090000623 proteins and genes Proteins 0.000 description 51
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 49
• 102000004169 proteins and genes Human genes 0.000 description 49
• 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 47
• 102000052611 human IL6 Human genes 0.000 description 47
• 208000030533 eye disease Diseases 0.000 description 44
• 102000004196 processed proteins & peptides Human genes 0.000 description 44
• 235000018102 proteins Nutrition 0.000 description 44
• 239000005557 antagonist Substances 0.000 description 42
• 230000009885 systemic effect Effects 0.000 description 42
• 230000011664 signaling Effects 0.000 description 36
• 238000002347 injection Methods 0.000 description 35
• 239000007924 injection Substances 0.000 description 35
• 229920000642 polymer Polymers 0.000 description 35
• 229920001184 polypeptide Polymers 0.000 description 33
• 125000003275 alpha amino acid group Chemical group 0.000 description 32
• -1 e.g. Proteins 0.000 description 31
• 230000002829 reductive effect Effects 0.000 description 31
• 238000009472 formulation Methods 0.000 description 28
• 102200123491 rs72555390 Human genes 0.000 description 25
• 102220250470 rs774802052 Human genes 0.000 description 25
• 230000000694 effects Effects 0.000 description 24
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 23
• 239000003814 drug Substances 0.000 description 23
• 239000002953 phosphate buffered saline Substances 0.000 description 23
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 21
• 239000011159 matrix material Substances 0.000 description 21
• 206010060823 Choroidal neovascularisation Diseases 0.000 description 20
• 230000000295 complement effect Effects 0.000 description 20
• 239000003112 inhibitor Substances 0.000 description 20
• 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 18
• 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 description 18
• 238000006467 substitution reaction Methods 0.000 description 17
• 102220528674 Bcl-2 homologous antagonist/killer_A28V_mutation Human genes 0.000 description 16
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 16
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 16
• 102220643083 Interleukin-31 receptor subunit alpha_S30P_mutation Human genes 0.000 description 16
• 210000001519 tissue Anatomy 0.000 description 16
• 241001465754 Metazoa Species 0.000 description 15
• 239000003795 chemical substances by application Substances 0.000 description 15
• 238000002474 experimental method Methods 0.000 description 15
• 239000002245 particle Substances 0.000 description 15
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
• 230000000875 corresponding effect Effects 0.000 description 14
• 208000035475 disorder Diseases 0.000 description 14
• 238000012360 testing method Methods 0.000 description 14
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 13
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 13
• 125000000539 amino acid group Chemical group 0.000 description 13
• 229940079593 drug Drugs 0.000 description 13
• 230000014509 gene expression Effects 0.000 description 13
• 239000000178 monomer Substances 0.000 description 13
• 238000002560 therapeutic procedure Methods 0.000 description 13
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
• 150000001875 compounds Chemical class 0.000 description 12
• 230000007423 decrease Effects 0.000 description 12
• 230000005764 inhibitory process Effects 0.000 description 12
• 235000002639 sodium chloride Nutrition 0.000 description 12
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 12
• 241001529936 Murinae Species 0.000 description 11
• 241000699666 Mus <mouse, genus> Species 0.000 description 11
• 238000009825 accumulation Methods 0.000 description 11
• 230000000699 topical effect Effects 0.000 description 11
• 239000013598 vector Substances 0.000 description 11
• 241000699670 Mus sp. Species 0.000 description 10
• 241000283973 Oryctolagus cuniculus Species 0.000 description 10
• 230000008485 antagonism Effects 0.000 description 10
• 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
• 210000004408 hybridoma Anatomy 0.000 description 10
• 102000005962 receptors Human genes 0.000 description 10
• 108020003175 receptors Proteins 0.000 description 10
• 238000004007 reversed phase HPLC Methods 0.000 description 10
• 230000001225 therapeutic effect Effects 0.000 description 10
• 241000700159 Rattus Species 0.000 description 9
• 229920002125 Sokalan® Polymers 0.000 description 9
• 239000002253 acid Substances 0.000 description 9
• 230000002776 aggregation Effects 0.000 description 9
• 238000004220 aggregation Methods 0.000 description 9
• 229920001577 copolymer Polymers 0.000 description 9
• 238000010494 dissociation reaction Methods 0.000 description 9
• 230000005593 dissociations Effects 0.000 description 9
• 239000007943 implant Substances 0.000 description 9
• 239000002773 nucleotide Substances 0.000 description 9
• 125000003729 nucleotide group Chemical group 0.000 description 9
• 210000001525 retina Anatomy 0.000 description 9
• 239000006228 supernatant Substances 0.000 description 9
• 206010010984 Corneal abrasion Diseases 0.000 description 8
• 208000028006 Corneal injury Diseases 0.000 description 8
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
• 238000002835 absorbance Methods 0.000 description 8
• 230000008901 benefit Effects 0.000 description 8
• 238000004422 calculation algorithm Methods 0.000 description 8
• 210000003161 choroid Anatomy 0.000 description 8
• 239000013078 crystal Substances 0.000 description 8
• 230000006378 damage Effects 0.000 description 8
• 238000005516 engineering process Methods 0.000 description 8
• 238000004519 manufacturing process Methods 0.000 description 8
• 230000001404 mediated effect Effects 0.000 description 8
• 241000894007 species Species 0.000 description 8
• 208000024891 symptom Diseases 0.000 description 8
• 229940124597 therapeutic agent Drugs 0.000 description 8
• 108010038501 Interleukin-6 Receptors Proteins 0.000 description 7
• 102000010781 Interleukin-6 Receptors Human genes 0.000 description 7
• 108091028043 Nucleic acid sequence Proteins 0.000 description 7
• 241000288906 Primates Species 0.000 description 7
• 210000004899 c-terminal region Anatomy 0.000 description 7
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
• 239000003431 cross linking reagent Substances 0.000 description 7
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 7
• 238000012377 drug delivery Methods 0.000 description 7
• 239000012530 fluid Substances 0.000 description 7
• 230000002401 inhibitory effect Effects 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 229910052698 phosphorus Inorganic materials 0.000 description 7
• 210000002381 plasma Anatomy 0.000 description 7
• 239000011780 sodium chloride Substances 0.000 description 7
• 239000000725 suspension Substances 0.000 description 7
• 230000008685 targeting Effects 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• 241000282552 Chlorocebus aethiops Species 0.000 description 6
• 150000008574 D-amino acids Chemical class 0.000 description 6
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 6
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
• 206010061218 Inflammation Diseases 0.000 description 6
• 206010029113 Neovascularisation Diseases 0.000 description 6
• DPYXMBSGNBXBRW-NAGRZYTCSA-O [[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[(2r,3s,4r,5r)-5-[2-(dimethylamino)-7-methyl-6-oxo-3h-purin-9-ium-9-yl]-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound C1=NC(C(N=C(N)N2)=O)=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1[N+]1=CN(C)C2=C1NC(N(C)C)=NC2=O DPYXMBSGNBXBRW-NAGRZYTCSA-O 0.000 description 6
• 230000033115 angiogenesis Effects 0.000 description 6
• 239000002585 base Substances 0.000 description 6
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
• 239000000872 buffer Substances 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 230000004540 complement-dependent cytotoxicity Effects 0.000 description 6
• 235000018417 cysteine Nutrition 0.000 description 6
• 230000003247 decreasing effect Effects 0.000 description 6
• 238000009826 distribution Methods 0.000 description 6
• 229940051306 eylea Drugs 0.000 description 6
• 230000000670 limiting effect Effects 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 239000004584 polyacrylic acid Substances 0.000 description 6
• 210000003786 sclera Anatomy 0.000 description 6
• 230000032258 transport Effects 0.000 description 6
• 239000003981 vehicle Substances 0.000 description 6
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
• 208000005024 Castleman disease Diseases 0.000 description 5
• 108060003951 Immunoglobulin Proteins 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• 238000004458 analytical method Methods 0.000 description 5
• 210000001742 aqueous humor Anatomy 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 235000011089 carbon dioxide Nutrition 0.000 description 5
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
• 238000010790 dilution Methods 0.000 description 5
• 239000012895 dilution Substances 0.000 description 5
• 239000012636 effector Substances 0.000 description 5
• 239000010408 film Substances 0.000 description 5
• 239000000499 gel Substances 0.000 description 5
• 102000018358 immunoglobulin Human genes 0.000 description 5
• 230000004054 inflammatory process Effects 0.000 description 5
• 208000014674 injury Diseases 0.000 description 5
• 239000003456 ion exchange resin Substances 0.000 description 5
• 229920003303 ion-exchange polymer Polymers 0.000 description 5
• 239000012669 liquid formulation Substances 0.000 description 5
• 239000004005 microsphere Substances 0.000 description 5
• 238000002823 phage display Methods 0.000 description 5
• 229920001610 polycaprolactone Polymers 0.000 description 5
• 239000004632 polycaprolactone Substances 0.000 description 5
• 239000013641 positive control Substances 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 150000003839 salts Chemical class 0.000 description 5
• 238000012216 screening Methods 0.000 description 5
• 239000000375 suspending agent Substances 0.000 description 5
• 230000000007 visual effect Effects 0.000 description 5
• 210000004127 vitreous body Anatomy 0.000 description 5
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
• NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 4
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
• 229930182816 L-glutamine Natural products 0.000 description 4
• 229920001213 Polysorbate 20 Polymers 0.000 description 4
• 208000027418 Wounds and injury Diseases 0.000 description 4
• 239000002671 adjuvant Substances 0.000 description 4
• 239000012911 assay medium Substances 0.000 description 4
• 210000003719 b-lymphocyte Anatomy 0.000 description 4
• 229920002988 biodegradable polymer Polymers 0.000 description 4
• 229920013641 bioerodible polymer Polymers 0.000 description 4
• 238000004587 chromatography analysis Methods 0.000 description 4
• 238000003776 cleavage reaction Methods 0.000 description 4
• 210000004087 cornea Anatomy 0.000 description 4
• 229920006037 cross link polymer Polymers 0.000 description 4
• 150000002009 diols Chemical class 0.000 description 4
• 230000008030 elimination Effects 0.000 description 4
• 238000003379 elimination reaction Methods 0.000 description 4
• 210000000744 eyelid Anatomy 0.000 description 4
• 230000004927 fusion Effects 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 239000008103 glucose Substances 0.000 description 4
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
• 230000003053 immunization Effects 0.000 description 4
• 238000002649 immunization Methods 0.000 description 4
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 238000013507 mapping Methods 0.000 description 4
• 239000002105 nanoparticle Substances 0.000 description 4
• 239000002674 ointment Substances 0.000 description 4
• 230000003204 osmotic effect Effects 0.000 description 4
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 4
• 229920001223 polyethylene glycol Polymers 0.000 description 4
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
• 229920002451 polyvinyl alcohol Polymers 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 229960003876 ranibizumab Drugs 0.000 description 4
• 238000006722 reduction reaction Methods 0.000 description 4
• 230000007017 scission Effects 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 150000003431 steroids Chemical class 0.000 description 4
• 238000003146 transient transfection Methods 0.000 description 4
• SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 3
• NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 3
• 241000282832 Camelidae Species 0.000 description 3
• 208000034628 Celiac artery compression syndrome Diseases 0.000 description 3
• 229920001661 Chitosan Polymers 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
• 229920002148 Gellan gum Polymers 0.000 description 3
• 208000010412 Glaucoma Diseases 0.000 description 3
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
• 208000003456 Juvenile Arthritis Diseases 0.000 description 3
• 150000008575 L-amino acids Chemical class 0.000 description 3
• 241000282567 Macaca fascicularis Species 0.000 description 3
• 208000001344 Macular Edema Diseases 0.000 description 3
• 206010025415 Macular oedema Diseases 0.000 description 3
• 239000004721 Polyphenylene oxide Substances 0.000 description 3
• 239000004372 Polyvinyl alcohol Substances 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 3
• 208000007135 Retinal Neovascularization Diseases 0.000 description 3
• 102100038247 Retinol-binding protein 3 Human genes 0.000 description 3
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
• 208000000208 Wet Macular Degeneration Diseases 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 238000000149 argon plasma sintering Methods 0.000 description 3
• 229960000397 bevacizumab Drugs 0.000 description 3
• 230000015572 biosynthetic process Effects 0.000 description 3
• 229920001400 block copolymer Chemical class 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 230000003197 catalytic effect Effects 0.000 description 3
• 238000001516 cell proliferation assay Methods 0.000 description 3
• 239000006285 cell suspension Substances 0.000 description 3
• 230000008859 change Effects 0.000 description 3
• 239000003638 chemical reducing agent Substances 0.000 description 3
• 238000005094 computer simulation Methods 0.000 description 3
• 230000003013 cytotoxicity Effects 0.000 description 3
• 231100000135 cytotoxicity Toxicity 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• 238000002022 differential scanning fluorescence spectroscopy Methods 0.000 description 3
• 238000004090 dissolution Methods 0.000 description 3
• 229940088598 enzyme Drugs 0.000 description 3
• RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
• 239000013604 expression vector Substances 0.000 description 3
• 238000005194 fractionation Methods 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 150000004676 glycans Chemical class 0.000 description 3
• 229920003063 hydroxymethyl cellulose Polymers 0.000 description 3
• 229940031574 hydroxymethyl cellulose Drugs 0.000 description 3
• 238000001727 in vivo Methods 0.000 description 3
• 230000002757 inflammatory effect Effects 0.000 description 3
• 238000003780 insertion Methods 0.000 description 3
• 230000037431 insertion Effects 0.000 description 3
• 108010048996 interstitial retinol-binding protein Proteins 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 230000004410 intraocular pressure Effects 0.000 description 3
• 208000028867 ischemia Diseases 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 210000002751 lymph Anatomy 0.000 description 3
• 201000010230 macular retinal edema Diseases 0.000 description 3
• 238000000569 multi-angle light scattering Methods 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 3
• 229920000570 polyether Polymers 0.000 description 3
• 229920002635 polyurethane Polymers 0.000 description 3
• 239000004814 polyurethane Substances 0.000 description 3
• 238000002818 protein evolution Methods 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 206010039073 rheumatoid arthritis Diseases 0.000 description 3
• 102200007396 rs747981483 Human genes 0.000 description 3
• 238000002741 site-directed mutagenesis Methods 0.000 description 3
• 239000000758 substrate Substances 0.000 description 3
• 230000009261 transgenic effect Effects 0.000 description 3
• 238000011830 transgenic mouse model Methods 0.000 description 3
• QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 2
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
• MYRTYDVEIRVNKP-UHFFFAOYSA-N 1,2-Divinylbenzene Chemical compound C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 2
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
• 208000026326 Adult-onset Still disease Diseases 0.000 description 2
• 229920000936 Agarose Polymers 0.000 description 2
• 108700028369 Alleles Proteins 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• UIERETOOQGIECD-UHFFFAOYSA-N Angelic acid Natural products CC=C(C)C(O)=O UIERETOOQGIECD-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 241000282693 Cercopithecidae Species 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• 102000004127 Cytokines Human genes 0.000 description 2
• 108090000695 Cytokines Proteins 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
• 239000005977 Ethylene Substances 0.000 description 2
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
• 206010015958 Eye pain Diseases 0.000 description 2
• 102100037362 Fibronectin Human genes 0.000 description 2
• 102000002090 Fibronectin type III Human genes 0.000 description 2
• 108050009401 Fibronectin type III Proteins 0.000 description 2
• 108010067306 Fibronectins Proteins 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• 241000219726 Griffonia simplicifolia Species 0.000 description 2
• 239000007995 HEPES buffer Substances 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• 241000282560 Macaca mulatta Species 0.000 description 2
• CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
• 239000004677 Nylon Substances 0.000 description 2
• 208000037273 Pathologic Processes Diseases 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 229920001710 Polyorthoester Polymers 0.000 description 2
• 102220630210 Protein amnionless_R24E_mutation Human genes 0.000 description 2
• 108020004511 Recombinant DNA Proteins 0.000 description 2
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
• UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
• 206010065647 Systemic leakage Diseases 0.000 description 2
• 108700019146 Transgenes Proteins 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 230000009824 affinity maturation Effects 0.000 description 2
• 239000011543 agarose gel Substances 0.000 description 2
• 230000004520 agglutination Effects 0.000 description 2
• 230000003042 antagnostic effect Effects 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 230000009830 antibody antigen interaction Effects 0.000 description 2
• 230000005875 antibody response Effects 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 238000013459 approach Methods 0.000 description 2
• MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
• 239000004621 biodegradable polymer Substances 0.000 description 2
• 230000008827 biological function Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 210000004240 ciliary body Anatomy 0.000 description 2
• 210000000795 conjunctiva Anatomy 0.000 description 2
• 230000002596 correlated effect Effects 0.000 description 2
• 238000004132 cross linking Methods 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• 229910052805 deuterium Inorganic materials 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 2
• 230000002255 enzymatic effect Effects 0.000 description 2
• FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 238000001879 gelation Methods 0.000 description 2
• 235000010492 gellan gum Nutrition 0.000 description 2
• 239000000216 gellan gum Substances 0.000 description 2
• 230000036541 health Effects 0.000 description 2
• 239000008241 heterogeneous mixture Substances 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 208000027866 inflammatory disease Diseases 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 230000017306 interleukin-6 production Effects 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 238000011835 investigation Methods 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 238000011068 loading method Methods 0.000 description 2
• 238000004020 luminiscence type Methods 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 150000002734 metacrylic acid derivatives Chemical class 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 238000002703 mutagenesis Methods 0.000 description 2
• 231100000350 mutagenesis Toxicity 0.000 description 2
• 229920001778 nylon Polymers 0.000 description 2
• PMOWTIHVNWZYFI-UHFFFAOYSA-N o-Coumaric acid Natural products OC(=O)C=CC1=CC=CC=C1O PMOWTIHVNWZYFI-UHFFFAOYSA-N 0.000 description 2
• 230000009054 pathological process Effects 0.000 description 2
• 238000012510 peptide mapping method Methods 0.000 description 2
• 230000035479 physiological effects, processes and functions Effects 0.000 description 2
• 229920001983 poloxamer Polymers 0.000 description 2
• 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
• 229920000747 poly(lactic acid) Polymers 0.000 description 2
• 229920001282 polysaccharide Polymers 0.000 description 2
• 239000005017 polysaccharide Substances 0.000 description 2
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 238000004064 recycling Methods 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 239000001632 sodium acetate Substances 0.000 description 2
• 235000017281 sodium acetate Nutrition 0.000 description 2
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
• 229960001922 sodium perborate Drugs 0.000 description 2
• YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 2
• 239000008247 solid mixture Substances 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 239000004173 sunset yellow FCF Substances 0.000 description 2
• 238000013268 sustained release Methods 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 239000012049 topical pharmaceutical composition Substances 0.000 description 2
• 230000001988 toxicity Effects 0.000 description 2
• 231100000419 toxicity Toxicity 0.000 description 2
• PMOWTIHVNWZYFI-AATRIKPKSA-N trans-2-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1O PMOWTIHVNWZYFI-AATRIKPKSA-N 0.000 description 2
• 238000012448 transchromosomic mouse model Methods 0.000 description 2
• 239000012096 transfection reagent Substances 0.000 description 2
• 230000010474 transient expression Effects 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 230000007306 turnover Effects 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• BSUKKOMNQGNSGP-QPJJXVBHSA-N (2e)-2-ethylidenehexanoic acid Chemical compound CCCC\C(=C/C)C(O)=O BSUKKOMNQGNSGP-QPJJXVBHSA-N 0.000 description 1
• KHQDAOSIOHTJCX-OWOJBTEDSA-N (E)-3-(4,4-dihydroxycyclohexa-1,5-dien-1-yl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CCC(O)(O)C=C1 KHQDAOSIOHTJCX-OWOJBTEDSA-N 0.000 description 1
• IAKAIJRXUQFDRQ-ZPYUXNTASA-N (e)-but-2-enoic acid;2-methylprop-2-enoic acid Chemical compound C\C=C\C(O)=O.CC(=C)C(O)=O IAKAIJRXUQFDRQ-ZPYUXNTASA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• HGEFWFBFQKWVMY-DUXPYHPUSA-N 2,4-dihydroxy-trans cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1O HGEFWFBFQKWVMY-DUXPYHPUSA-N 0.000 description 1
• DSAYAFZWRDYBQY-UHFFFAOYSA-N 2,5-dimethylhexa-1,5-diene Chemical compound CC(=C)CCC(C)=C DSAYAFZWRDYBQY-UHFFFAOYSA-N 0.000 description 1
• GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
• UIERETOOQGIECD-ARJAWSKDSA-M 2-Methyl-2-butenoic acid Natural products C\C=C(\C)C([O-])=O UIERETOOQGIECD-ARJAWSKDSA-M 0.000 description 1
• RYNDYESLUKWOEE-UHFFFAOYSA-N 2-benzylprop-2-enoic acid Chemical compound OC(=O)C(=C)CC1=CC=CC=C1 RYNDYESLUKWOEE-UHFFFAOYSA-N 0.000 description 1
• FQHUWSPRTMWLFA-UHFFFAOYSA-N 2-cyclohexylprop-2-enoic acid Chemical compound OC(=O)C(=C)C1CCCCC1 FQHUWSPRTMWLFA-UHFFFAOYSA-N 0.000 description 1
• WROUWQQRXUBECT-UHFFFAOYSA-N 2-ethylacrylic acid Chemical compound CCC(=C)C(O)=O WROUWQQRXUBECT-UHFFFAOYSA-N 0.000 description 1
• 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 description 1
• RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 1
• ONPJWQSDZCGSQM-UHFFFAOYSA-N 2-phenylprop-2-enoic acid Chemical compound OC(=O)C(=C)C1=CC=CC=C1 ONPJWQSDZCGSQM-UHFFFAOYSA-N 0.000 description 1
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
• BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
• QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 description 1
• CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
• DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
• 229940117976 5-hydroxylysine Drugs 0.000 description 1
• 208000033316 Acquired hemophilia A Diseases 0.000 description 1
• NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
• 108010088751 Albumins Proteins 0.000 description 1
• 102000009027 Albumins Human genes 0.000 description 1
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 235000002198 Annona diversifolia Nutrition 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 238000011725 BALB/c mouse Methods 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 102100032305 Bcl-2 homologous antagonist/killer Human genes 0.000 description 1
• 208000009137 Behcet syndrome Diseases 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 241000282465 Canis Species 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 108020004635 Complementary DNA Proteins 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 239000004971 Cross linker Substances 0.000 description 1
• 229920001651 Cyanoacrylate Polymers 0.000 description 1
• 229920000858 Cyclodextrin Polymers 0.000 description 1
• 102000018832 Cytochromes Human genes 0.000 description 1
• 108010052832 Cytochromes Proteins 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 101150082070 Dab gene Proteins 0.000 description 1
• 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 1
• 208000002249 Diabetes Complications Diseases 0.000 description 1
• 206010012655 Diabetic complications Diseases 0.000 description 1
• 206010012692 Diabetic uveitis Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
• 229920003134 Eudragit® polymer Polymers 0.000 description 1
• 206010015548 Euthanasia Diseases 0.000 description 1
• 102000009109 Fc receptors Human genes 0.000 description 1
• 108010087819 Fc receptors Proteins 0.000 description 1
• 239000012743 FreeStyle Max reagent Substances 0.000 description 1
• 208000003098 Ganglion Cysts Diseases 0.000 description 1
• 208000007465 Giant cell arteritis Diseases 0.000 description 1
• 208000009329 Graft vs Host Disease Diseases 0.000 description 1
• 102220536710 Hemoglobin subunit epsilon_H90N_mutation Human genes 0.000 description 1
• 101000777314 Homo sapiens Choline kinase alpha Proteins 0.000 description 1
• 101000777313 Homo sapiens Choline/ethanolamine kinase Proteins 0.000 description 1
• 101001138544 Homo sapiens UMP-CMP kinase Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 238000012450 HuMAb Mouse Methods 0.000 description 1
• 108090000144 Human Proteins Proteins 0.000 description 1
• 102000003839 Human Proteins Human genes 0.000 description 1
• 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
• WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 102220467434 Hypoxia-inducible lipid droplet-associated protein_K27E_mutation Human genes 0.000 description 1
• 101150101999 IL6 gene Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
• 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
• 238000012449 Kunming mouse Methods 0.000 description 1
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
• 241000282838 Lama Species 0.000 description 1
• 239000004166 Lanolin Substances 0.000 description 1
• 108090001090 Lectins Proteins 0.000 description 1
• 102000004856 Lectins Human genes 0.000 description 1
• 102000019298 Lipocalin Human genes 0.000 description 1
• 108050006654 Lipocalin Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
• MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
• 208000034578 Multiple myelomas Diseases 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 101001076414 Mus musculus Interleukin-6 Proteins 0.000 description 1
• 201000002481 Myositis Diseases 0.000 description 1
• JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• QDFKDDCKKXSMEJ-UHFFFAOYSA-N OC(=O)C=CC1=CC=CC=C1.OC(=O)C(=C)C1=CC=CC=C1 Chemical compound OC(=O)C=CC1=CC=CC=C1.OC(=O)C(=C)C1=CC=CC=C1 QDFKDDCKKXSMEJ-UHFFFAOYSA-N 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 108010082522 Oncostatin M Receptors Proteins 0.000 description 1
• 102100030098 Oncostatin-M-specific receptor subunit beta Human genes 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
• 102220621769 Pentraxin-4_H86N_mutation Human genes 0.000 description 1
• 102000057297 Pepsin A Human genes 0.000 description 1
• 108090000284 Pepsin A Proteins 0.000 description 1
• 239000004264 Petrolatum Substances 0.000 description 1
• 208000007452 Plasmacytoma Diseases 0.000 description 1
• 241000276498 Pollachius virens Species 0.000 description 1
• RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
• 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 229920000148 Polycarbophil calcium Polymers 0.000 description 1
• 206010065159 Polychondritis Diseases 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
• 206010060862 Prostate cancer Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102220630212 Protein amnionless_R30E_mutation Human genes 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 239000012980 RPMI-1640 medium Substances 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 101001076459 Rattus norvegicus Interleukin-6 Proteins 0.000 description 1
• 108700008625 Reporter Genes Proteins 0.000 description 1
• 206010038923 Retinopathy Diseases 0.000 description 1
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 241000220010 Rhode Species 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
• 102000054727 Serum Amyloid A Human genes 0.000 description 1
• 108700028909 Serum Amyloid A Proteins 0.000 description 1
• 241000705082 Sialia Species 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 102220506631 Small ubiquitin-related modifier 3_I33A_mutation Human genes 0.000 description 1
• 102400001298 Soluble interleukin-6 receptor subunit alpha Human genes 0.000 description 1
• 101800001839 Soluble interleukin-6 receptor subunit alpha Proteins 0.000 description 1
• 102220616771 Son of sevenless homolog 1_H86A_mutation Human genes 0.000 description 1
• 102220616772 Son of sevenless homolog 1_H90A_mutation Human genes 0.000 description 1
• 101000677856 Stenotrophomonas maltophilia (strain K279a) Actin-binding protein Smlt3054 Proteins 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 208000005400 Synovial Cyst Diseases 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 208000001106 Takayasu Arteritis Diseases 0.000 description 1
• 240000004584 Tamarindus indica Species 0.000 description 1
• 235000004298 Tamarindus indica Nutrition 0.000 description 1
• 102100024554 Tetranectin Human genes 0.000 description 1
• 229920002807 Thiomer Polymers 0.000 description 1
• 102000004338 Transferrin Human genes 0.000 description 1
• 108090000901 Transferrin Proteins 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
• 208000035868 Vascular inflammations Diseases 0.000 description 1
• XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
• 229920002000 Xyloglucan Polymers 0.000 description 1
• 229910021536 Zeolite Inorganic materials 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 238000000246 agarose gel electrophoresis Methods 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
• 150000001412 amines Chemical class 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
• 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
• 235000011130 ammonium sulphate Nutrition 0.000 description 1
• 206010002022 amyloidosis Diseases 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• UIERETOOQGIECD-ARJAWSKDSA-N angelic acid Chemical compound C\C=C(\C)C(O)=O UIERETOOQGIECD-ARJAWSKDSA-N 0.000 description 1
• 238000002583 angiography Methods 0.000 description 1
• 150000001450 anions Chemical class 0.000 description 1
• 238000011230 antibody-based therapy Methods 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000007900 aqueous suspension Substances 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 201000004982 autoimmune uveitis Diseases 0.000 description 1
• 229940125717 barbiturate Drugs 0.000 description 1
• HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• BBWBEZAMXFGUGK-UHFFFAOYSA-N bis(dodecylsulfanyl)-methylarsane Chemical compound CCCCCCCCCCCCS[As](C)SCCCCCCCCCCCC BBWBEZAMXFGUGK-UHFFFAOYSA-N 0.000 description 1
• 210000001124 body fluid Anatomy 0.000 description 1
• 239000010839 body fluid Substances 0.000 description 1
• 230000036760 body temperature Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 229910021538 borax Inorganic materials 0.000 description 1
• 239000006172 buffering agent Substances 0.000 description 1
• DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
• CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 238000005251 capillar electrophoresis Methods 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 125000004432 carbon atom Chemical group C* 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 229960001777 castor oil Drugs 0.000 description 1
• 238000005277 cation exchange chromatography Methods 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000024245 cell differentiation Effects 0.000 description 1
• 230000006727 cell loss Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 238000012054 celltiter-glo Methods 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 238000006243 chemical reaction Methods 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 229960003260 chlorhexidine Drugs 0.000 description 1
• 239000007979 citrate buffer Substances 0.000 description 1
• 230000010405 clearance mechanism Effects 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• 238000004590 computer program Methods 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 230000008878 coupling Effects 0.000 description 1
• 238000010168 coupling process Methods 0.000 description 1
• 238000005859 coupling reaction Methods 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 150000001945 cysteines Chemical class 0.000 description 1
• 238000007405 data analysis Methods 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 239000008367 deionised water Substances 0.000 description 1
• 229910021641 deionized water Inorganic materials 0.000 description 1
• 238000002716 delivery method Methods 0.000 description 1
• YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 238000013461 design Methods 0.000 description 1
• 230000001627 detrimental effect Effects 0.000 description 1
• 125000004386 diacrylate group Chemical group 0.000 description 1
• 238000009792 diffusion process Methods 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 210000003717 douglas' pouch Anatomy 0.000 description 1
• 229940000406 drug candidate Drugs 0.000 description 1
• 210000003162 effector t lymphocyte Anatomy 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000002158 endotoxin Substances 0.000 description 1
• YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 1
• 239000005038 ethylene vinyl acetate Substances 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
• 229960001347 fluocinolone acetonide Drugs 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 238000001476 gene delivery Methods 0.000 description 1
• 238000012239 gene modification Methods 0.000 description 1
• 230000005017 genetic modification Effects 0.000 description 1
• 235000013617 genetically modified food Nutrition 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 208000024908 graft versus host disease Diseases 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• PSTBYXSYWMQNJV-UHFFFAOYSA-N hexa-1,5-diene-2,3-diol Chemical compound OC(=C)C(O)CC=C PSTBYXSYWMQNJV-UHFFFAOYSA-N 0.000 description 1
• KUQWZSZYIQGTHT-UHFFFAOYSA-N hexa-1,5-diene-3,4-diol Chemical compound C=CC(O)C(O)C=C KUQWZSZYIQGTHT-UHFFFAOYSA-N 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
• 201000001421 hyperglycemia Diseases 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
• 229960002411 imatinib Drugs 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 230000016784 immunoglobulin production Effects 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000008798 inflammatory stress Effects 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 239000012948 isocyanate Substances 0.000 description 1
• 150000002513 isocyanates Chemical class 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 229940060928 lacrisert Drugs 0.000 description 1
• 108010032674 lampalizumab Proteins 0.000 description 1
• 229950000482 lampalizumab Drugs 0.000 description 1
• 229940039717 lanolin Drugs 0.000 description 1
• 235000019388 lanolin Nutrition 0.000 description 1
• 238000013532 laser treatment Methods 0.000 description 1
• 239000002523 lectin Substances 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
• YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
• 150000002632 lipids Chemical class 0.000 description 1
• 230000002132 lysosomal effect Effects 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 239000000155 melt Substances 0.000 description 1
• 108020004999 messenger RNA Proteins 0.000 description 1
• 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 210000002500 microbody Anatomy 0.000 description 1
• 239000011859 microparticle Substances 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 201000006417 multiple sclerosis Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• BLYOHBPLFYXHQA-UHFFFAOYSA-N n,n-bis(prop-2-enyl)prop-2-enamide Chemical compound C=CCN(CC=C)C(=O)C=C BLYOHBPLFYXHQA-UHFFFAOYSA-N 0.000 description 1
• OVHHHVAVHBHXAK-UHFFFAOYSA-N n,n-diethylprop-2-enamide Chemical compound CCN(CC)C(=O)C=C OVHHHVAVHBHXAK-UHFFFAOYSA-N 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 230000006576 neuronal survival Effects 0.000 description 1
• 238000011587 new zealand white rabbit Methods 0.000 description 1
• NZIDBRBFGPQCRY-UHFFFAOYSA-N octyl 2-methylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C(C)=C NZIDBRBFGPQCRY-UHFFFAOYSA-N 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 230000006548 oncogenic transformation Effects 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 230000006320 pegylation Effects 0.000 description 1
• WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
• PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
• 229940111202 pepsin Drugs 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 229940066842 petrolatum Drugs 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 239000003208 petroleum Substances 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 230000003285 pharmacodynamic effect Effects 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 230000001766 physiological effect Effects 0.000 description 1
• 229960001416 pilocarpine Drugs 0.000 description 1
• 230000004983 pleiotropic effect Effects 0.000 description 1
• 229960000502 poloxamer Drugs 0.000 description 1
• 229920000962 poly(amidoamine) Polymers 0.000 description 1
• 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
• 239000002745 poly(ortho ester) Substances 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 208000019764 polyarticular juvenile idiopathic arthritis Diseases 0.000 description 1
• 229950005134 polycarbophil Drugs 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 239000002685 polymerization catalyst Substances 0.000 description 1
• 238000006116 polymerization reaction Methods 0.000 description 1
• 230000000379 polymerizing effect Effects 0.000 description 1
• 208000005987 polymyositis Diseases 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920005862 polyol Polymers 0.000 description 1
• 150000003077 polyols Chemical class 0.000 description 1
• 229920001299 polypropylene fumarate Polymers 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 239000011164 primary particle Substances 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 230000008569 process Effects 0.000 description 1
• 238000003672 processing method Methods 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 229960003981 proparacaine Drugs 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 230000004845 protein aggregation Effects 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 108020001580 protein domains Proteins 0.000 description 1
• 230000005588 protonation Effects 0.000 description 1
• 239000008213 purified water Substances 0.000 description 1
• 238000010526 radical polymerization reaction Methods 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 238000009790 rate-determining step (RDS) Methods 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 208000009169 relapsing polychondritis Diseases 0.000 description 1
• 230000010410 reperfusion Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 210000001210 retinal vessel Anatomy 0.000 description 1
• 229940061341 retisert Drugs 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 201000003068 rheumatic fever Diseases 0.000 description 1
• 102220290783 rs1553255533 Human genes 0.000 description 1
• 239000012146 running buffer Substances 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 238000013341 scale-up Methods 0.000 description 1
• HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
• 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
• 229960002668 sodium chloride Drugs 0.000 description 1
• UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
• 229960002218 sodium chlorite Drugs 0.000 description 1
• 239000001509 sodium citrate Substances 0.000 description 1
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
• 235000011083 sodium citrates Nutrition 0.000 description 1
• 235000011121 sodium hydroxide Nutrition 0.000 description 1
• 239000001540 sodium lactate Substances 0.000 description 1
• 235000011088 sodium lactate Nutrition 0.000 description 1
• 229940005581 sodium lactate Drugs 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 235000011008 sodium phosphates Nutrition 0.000 description 1
• 235000010339 sodium tetraborate Nutrition 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 238000011272 standard treatment Methods 0.000 description 1
• 230000001954 sterilising effect Effects 0.000 description 1
• 238000004659 sterilization and disinfection Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 125000001424 substituent group Chemical group 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 235000000346 sugar Nutrition 0.000 description 1
• 150000005846 sugar alcohols Polymers 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000002459 sustained effect Effects 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 230000002194 synthesizing effect Effects 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 206010043207 temporal arteritis Diseases 0.000 description 1
• 238000010998 test method Methods 0.000 description 1
• 229960002372 tetracaine Drugs 0.000 description 1
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
• 108010013645 tetranectin Proteins 0.000 description 1
• 125000003396 thiol group Chemical group [H]S* 0.000 description 1
• DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
• UIERETOOQGIECD-ONEGZZNKSA-N tiglic acid Chemical compound C\C=C(/C)C(O)=O UIERETOOQGIECD-ONEGZZNKSA-N 0.000 description 1
• UAXOELSVPTZZQG-UHFFFAOYSA-N tiglic acid Natural products CC(C)=C(C)C(O)=O UAXOELSVPTZZQG-UHFFFAOYSA-N 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 231100000041 toxicology testing Toxicity 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 239000012581 transferrin Substances 0.000 description 1
• 230000014723 transformation of host cell by virus Effects 0.000 description 1
• 238000012451 transgenic animal system Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
• 230000008733 trauma Effects 0.000 description 1
• BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
• 229910052721 tungsten Inorganic materials 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 230000008728 vascular permeability Effects 0.000 description 1
• 239000002525 vasculotropin inhibitor Substances 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 239000004034 viscosity adjusting agent Substances 0.000 description 1
• 230000004304 visual acuity Effects 0.000 description 1
• 229920003176 water-insoluble polymer Polymers 0.000 description 1
• 229920003169 water-soluble polymer Polymers 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 238000002424 x-ray crystallography Methods 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• 229910052727 yttrium Inorganic materials 0.000 description 1
• 239000010457 zeolite Substances 0.000 description 1
• PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1